Metabolite impurities, also known as metabolic impurities, are substances that form when the body breaks down a drug through metabolic processes. These impurities can result from enzymatic reactions in the liver or other tissues and may include active or inactive metabolites. Monitoring metabolite impurities is crucial to ensure the safety, efficacy, and quality of drug substances. Regulatory guidelines emphasize their evaluation during drug development to minimize risks associated with their formation.
Parent: Alogliptin
Parent: Ametoctradin
Parent: Buspirone
Parent: Buspirone
Parent: Carvedilol
Parent: Leflunomide
During the development and testing of pharmaceuticals, it is essential to identify and control metabolite impurities and their related compounds. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), provide detailed guidance on the assessment and management of these impurities.
Key aspects include:
An impurity in a drug substance refers to any unwanted substance that arises during manufacturing, storage, or as a result of the drug’s degradation or metabolism. Impurities must be controlled to ensure the safety and efficacy of the drug.
A metabolite is a substance formed when the body processes or metabolizes a drug. Metabolites can be active, contributing to the therapeutic effects of the drug, or inactive, with no pharmacological activity.
Potential impurities in drug substances include related compounds from synthesis, degradation products formed during storage, residual solvents from manufacturing, and metabolite impurities formed in the body.
Examples of impurities in drugs include process-related impurities such as starting materials and intermediates, degradation products like oxidative or hydrolytic by-products, and metabolite impurities formed during drug metabolism.
